A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase I Study Evaluating Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of SOL-116 in Healthy Subjects and Patients With Rheumatoid Arthritis

This is a randomized, double-blind, placebo-controlled, first-in-human phase I study. It consists of a single ascending dose part in healthy subjects (Part 1) and in patients with rheumatoid arthritis (Part 2) as well as a multiple dose part in healthy subjects (Part 3). The study will collect information on pharmacokinetics, safety and tolerability.

开始日期2022-10-13

申办/合作机构

Lipum AB

[+1]

NCT05307406 / Completed临床1期

A First-in-Human Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Exploratory Markers of Efficacy for XAB05 in Healthy Subjects

This study is a randomized, placebo-controlled, first in human, single ascending dose Phase 1 study

开始日期2022-01-24

申办/合作机构

Xenothera SAS初创企业

[+1]

NL-OMON49143 / CompletedN/A

Pharmacokinetic and pharmacodynamic profile of midazolam intranasal spray in elderly volunteers. - CS0314 Midazolam

开始日期2020-03-11

申办/合作机构

QPS Netherlands BV

100 项与 QPS Netherlands BV 相关的临床结果

登录后查看更多信息

0 项与 QPS Netherlands BV 相关的专利（医药）

登录后查看更多信息

项与 QPS Netherlands BV 相关的文献（医药）

2020-06-01·Annals of the Rheumatic Diseases

THU0219 FIRST-INHUMAN STUDY OF SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF IRAK1/4 INHIBITOR R835 IN HEALTHY SUBJECTS

作者: H Zheng ; S Tong ; A Chow ; Izaak den Daas ; M Lee ; G Park ; V Taylor ; D Chow ; L Yan ; Anthony Absalom

Background:Toll-Like Receptors (TLR) and Interleukin-1 Receptors (IL-1R) play a critical role in the innate immune response as microbial and tissue damage sensors, providing a bridge between the innate and adaptive immunity. Interleukin receptor associated kinases (IRAK) 1 and 4 are serine/threonine kinases that are essential for signaling downstream of most TLRs and IL-1Rs and the resulting production of pro-inflammatory cytokines. Suppression of TLR and IL-1R signaling through inhibition of IRAK1/4 kinases is a promising therapeutic approach for the treatment of inflammatory and autoimmune diseases. We have identified a potent and selective IRAK1/4 inhibitor (R835) that showed dose-dependent inhibition of lipopolysaccharide (LPS, a TLR4 agonist), and IL-1β induced serum cytokines in mice. R835 prevented disease onset and progression in multiple rodent models of inflammatory diseases, including arthritis and lupus models.Objectives:The aim of this FIH study was to characterize the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of R835 after single or multiple dose oral administrations.Methods:This study was a randomized, placebo-controlled, double-blind Phase 1 study in healthy subjects in three parts: single ascending doses (20 mg-1920 mg, Part A) with food effect in a separate cohort (480 mg), multiple ascending doses (120 mg and 960 mg, BID, Part B) with a caffeine interaction (960 mg cohort), and an intravenous LPS challenge test at 240 mg oral dose of R835 (Part C).Results:Single doses of up to 480 mg R835 in organic solution, single doses of up to 1920 mg R835 as capsule, multiple doses of 120 mg R835 Q12H (organic solution), and 960 mg R835 Q12H (capsule) were safe and well tolerated. All R835 related adverse events (AEs) were mild in intensity and reversible, and mostly associated with the higher doses of R835 in the organic solution. The most common AEs were headache and gastrointestinal disturbance. The PK of R835 was linear and dose proportional in exposure over the dose range studied. A nominal level of accumulation in plasma achieved rapidly upon repeated BID administrations with steady-state essentially attained in 2 days. A high-fat meal with the capsule formulation resulted in slow rate of absorption but had no effect on the extent of absorption. There was no effect of R835 on metabolism of caffeine (P450 CYP1A2 prototype substrate). In the LPS challenge test, R835 profoundly inhibited the acute release of cytokines, including TNF-α, IL-6, IL-8, MIP1α and MIP1β, but had no impact on CRP release.Conclusion:R835 was well tolerated after single or multiple dose administrations. The most common AEs were headache and gastrointestinal disturbance. For both of the formulations tested, the PK of R835 was linear and exposure was dose proportional with rapid steady-state attainment following BID administration. There was no drug-drug interaction by use of caffeine as the protype substrate. R835 inhibited the LPS induced release of cytokines in the serum, including TNF-α, IL-6, IL-8, MIP1α and MIP1β, mirroring preclinical data in mice. The desirable PK and safety profile combined with proof of mechanism, as demonstrated by inhibition of cytokine release, support progression of R835 into Phase II clinical development as an agent for the treatment of inflammatory and autoimmune diseases.Disclosure of Interests: :Lucy Yan Shareholder of: Amgen, Rigel, Employee of: Amgen, Rigel, Sandra Tong Shareholder of: Rigel, Employee of: Rigel, Anthony Absalom: None declared, Izaak den Daas: None declared, Gary Park Shareholder of: Rigel Pharmaceuticals, Employee of: Rigel Pharmaceuticals, Vanessa Taylor Shareholder of: Rigel Pharmaceuticals, Employee of: Rigel Pharmaceuticals, Donna Chow Shareholder of: Rigel, Employee of: Rigel, Meng Lee Shareholder of: Rigel, Employee of: Rigel, Hanzhe Zheng Shareholder of: Rigel, Employee of: Rigel, Andrew Chow Shareholder of: Rigel, Employee of: Rigel

2015-04-01·Bioanalysis4区 · 医学

Robust, Fit-For-Purpose Method Transfer: Why We Should Apply Equivalence Testing

4区 · 医学

Article

作者: Wieling, Jaap

Efficient method transfer is the key in advancing drug candidates through development and requires careful planning and communication between the two laboratories. Successful transfers require robust bioanalytical methods that allow for some small deviations from the method in sender laboratory; however, by keeping the fundamentals of the sender method intact. The equivalence of data produced at both sides should be tested by mutually prepared and analyzed QCs and by analyzing incurred samples at both sides and assessed by a statistical equivalence testing. Current regulatory bodies’ guidances provide very limited direction for experimental setup and evaluation of transfer. This perspective paper gives an overview of the available approaches and proposes a way forward for the bioanalytical community.

2013-09-01·Bioanalysis4区 · 医学

In-Depth Study of Homogeneity in DBS Using Two Different Techniques: Results from The EBF DBS-Microsampling Consortium

4区 · 医学

Article

作者: de Vries, Ronald ; Schmid, Bernhard ; Staelens, Ludovicus ; van de Merbel, Nico ; Siethoff, Christoph ; Spooner, Neil ; Broadhurst, Rebecca ; Ortiz, Jordi ; Barfield, Matthew ; Doig, Mira ; White, Steve ; Cobb, Zoe ; van Baar, Ben ; Williams, Stephen ; Timmerman, Philip ; Verheij, Elwin

Background: At the start of their work, the European Bioanalysis Forum dried blood spots microsampling consortium did not form a dedicated team to investigate the spot homogeneity. However, two teams performed experiments that produced results relating to sample homogeneity. Results: The data, which were produced via two different approaches (a radiolabeled and a nonradiolabeled approach), are highly complementary and demonstrate clear effects on sample inhomogeneity due to the substrate type, compound and hematocrit levels. Conclusion: The results demonstrate that sample inhomogeneity is a significant hurdle to the use of dried blood spots for regulated bioanalysis that should be investigated further in the method establishment phase if the whole spot is not sampled.

100 项与 QPS Netherlands BV 相关的药物交易

登录后查看更多信息

100 项与 QPS Netherlands BV 相关的转化医学

登录后查看更多信息